Last reviewed · How we verify
NCT01775046
Valiant Thoracic Stent Graft With the Captivia Delivery System in the Treatment of Descending Thoracic Aortic Diseases (VALIANT CAPTIVIA France)
trial testing DTA patients (Valiant) in Aortic Aneurysm, Thoracic in 160 participants. Completed in 9 December 2021.
21 June 2021
Quick facts
| Lead sponsor | Medtronic Cardiovascular |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 160 |
| Start date | 23 March 2013 |
| Primary completion | 21 June 2021 |
| Estimated completion | 9 December 2021 |
| Sites | 17 locations across France |
Drugs / interventions tested
- DTA patients (Valiant)
Conditions studied
- Aortic Aneurysm, Thoracic — all drugs for Aortic Aneurysm, Thoracic →
- Descending Thoracic Aortic Dissection — all drugs for Descending Thoracic Aortic Dissection →
- Penetrating Ulcer — all drugs for Penetrating Ulcer →
- Aorta Thoracic; Traumatic Rupture — all drugs for Aorta Thoracic; Traumatic Rupture →
Sponsor
Medtronic Cardiovascular — full company profile →
Who can join
Eligibility, any sex, with Aortic Aneurysm, Thoracic or Descending Thoracic Aortic Dissection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to assess the benefits of endovascular technique in terms of efficacy and safety of Valiant Thoracic Stent Graft with the Captivia Delivery System in the treatment of thoracic aortic disease, in a cohort of patients representative of the population treated under real-life conditions of use in France for up to 5 years.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01775046
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aortic Aneurysm, Thoracic
Currently open trials in the same condition.
- NCT07034430 — Aortic Dilatation Under 5 cm: Genetic Risk Mapping · active not recruiting
Other Medtronic Cardiovascular trials
Trials by the same sponsor.
- NCT06906926 — Harmony TPV EMEA PMS · NA · recruiting
- NCT04982588 — Evolut PRO China Clinical Study · NA · active not recruiting
- NCT04639258 — Medtronic Evolut™ EXPAND TAVR I Feasibility Study · NA · terminated
- NCT04433065 — TTVR Early Feasibility Study · NA · recruiting
- NCT04267055 — DISSECT-N Post Market Data Collection Registry · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01775046 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medtronic Cardiovascular
- Last refreshed: 9 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01775046.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing